breaking news - update

BASF sees synergies between new acquisition Pronova and Equateq

By Gareth Macdonald contact

- Last updated on GMT

BASF wins over Pronova shareholders
BASF wins over Pronova shareholders

Related tags: Omega-3 fatty acids, Omega-3 fatty acid, Fatty acid, Basf

BASF has had its offer for omega-3 API maker Pronova Biopharma accepted by 97.7 per cent of the Norwiegan firm’s shareholders.

The deal – which will see the German firm pay around €684m for Pronova – was finally accepted last week after a bidding process that saw the German chemicals firm increase its offer​ in response to resistance from minority shareholders.

A BASF spokesman told today that: “We are confident that this is a good investment.

This acquisition will create numerous synergies by combining BASF’s global customer reach and many years of experience with Pronova’s solid know-how and scientific expertise in the production of highly concentrated omega-3 fatty acids, with the technology portfolio of Equateq [now operating under the name BASF Pharma Callanish]​.”

He explained that the aim of the deal was to strengthen BASF’s portfolio and expand its position in the research and development and manufacturing of omega-3 fatty acids for pharmaceutical and consumer health products.

BASF will have an attractive technology portfolio for developing and manufacturing omega-3 fatty acids. Highly concentrated omega-3 fatty acids are a globally growing market, driven by an increasing consumer awareness of omega-3 fatty acid health benefits​.”  

Pronova supplies GSK with the active pharmaceutical ingredient (API) for its heart pill Lovaza. BASF’s other omega-3 business – BASF Pharma Callanish -  is one of the firm’s for which Amarin is seeking US Food and Drug Administration (FDA) approval as a supplier for its rival product Vascepa​.

Fatty acid synergies

Pronova gives BASF capacity. The firm operates two production facilities – one in Norway and one in Denmark – which are capable of producing 2,500 tons of pharmaceutical grade omega-3 a year and employs around 311 people.

This contrasts with BASF Callanish, which has a single production facility on the Isle of Lewis in Scotland​.

The technology 'synergies' mentioned above are likely to involve the proprietary chromatographic separation methods in place at Callanish that - according to BASF​ - allow for more flexible blending and formulation of omega-3 fatty acids at exceptional purity levels.

Related news

Show more

Related products

show more

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Facilities: Lexington, KY USA

Facilities: Lexington, KY USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Lexington, KY USA is a fully integrated site which offers analytical, formulation development, and manufacturing...

Follow us


View more